Last reviewed · How we verify
Hypoparathyroidism
Approved treatments
- Yorvipath · Ascendis Pharma Bone
Palopegteriparatide releases PTH(1-34) to maintain calcium and phosphate homeostasis through PTH1R. - Infuvite Adult · Novartis
- Hornel · Taisho Pharmaceutical
- Vitamin D3
- Drisdol · Esjay Pharma
- Dichystrolum
Dichystrolum works by activating the Vitamin D3 receptor to increase calcium levels in the body. - Calciferol · Department of Medical Services Ministry of Public Health of Thailand
- Alfarol
Alfarol works by activating vitamin D receptors in the body, which helps regulate calcium levels. - Calcijex · Esjay Pharma
- Rocaltrol · Shandong University
- Alphacalcidol · University of Ioannina
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hypoparathyroidism patent landscape — cliff calendar, originator estates, attackable patents
- Hypoparathyroidism treatment landscape brief
- Hypoparathyroidism treatment updates RSS
Frequently asked questions about Hypoparathyroidism
What drugs treat Hypoparathyroidism?
Tracked treatments include Yorvipath, Infuvite Adult, Hornel, Vitamin D3, Drisdol, Dichystrolum, Calciferol, Alfarol.
What is the treatment for Hypoparathyroidism?
Standard treatment for Hypoparathyroidism includes Yorvipath, Infuvite Adult, Hornel, Vitamin D3, Drisdol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hypoparathyroidism patent cliff · Hypoparathyroidism CI report
- Treatment: Yorvipath · Ascendis Pharma Bone
- Treatment: Infuvite Adult · Novartis
- Treatment: Hornel · Taisho Pharmaceutical
- Treatment: Vitamin D3
- Treatment: Drisdol · Esjay Pharma
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing